全球首个双靶减重药物在北京大学人民医院开出全国首方

Core Viewpoint - The approval and prescription of Marsutide (brand name: Xinermai), the world's first dual-target weight loss drug combining glucagon (GCG) and glucagon-like peptide-1 (GLP-1), marks a significant advancement in obesity treatment in China [1][2]. Group 1: Product Overview - Marsutide was approved for market release on June 27, 2023, and is designed for long-term weight management in adults [1]. - The drug operates through a dual mechanism of action: it suppresses appetite via GLP-1 receptors and promotes fat burning through GCGR, addressing complex metabolic issues such as visceral fat accumulation and insulin resistance [2]. Group 2: Market Context - The obesity rate in China is rising, particularly among the young and middle-aged population, prompting increased public awareness and demand for professional weight management solutions [1]. - Patients seeking weight loss solutions often have previously attempted various methods without success, indicating a potential market for effective pharmaceutical interventions [2]. Group 3: Clinical Evidence - In clinical studies (GLORY-1), patients treated with Marsutide showed significant reductions in triglycerides and low-density lipoprotein cholesterol, with liver fat content decreasing by an average of 80% in those with fatty liver disease [1][2].